Dare Bioscience (DARE) Debt/Equity Ratio: History & Chart

Dare Bioscience, Inc.(DARE)

Biotechnology · San Diego, CA

$0.83-0.01 (-1.36%)

Delayed quote: Oct 6, 2026, 10:23 AM EDT

About Dare Bioscience, Inc.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

San Diego, CA

23 employees

darebioscience.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sabrina Martucci Johnson

View full financials

DARE Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

-12.08

DEBT TO EQUITY RATIO AVG TTM

-1.63

DEBT TO EQUITY RATIO AVG 3Y

-0.03

DEBT TO EQUITY RATIO AVG 5Y

-0.06

DEBT TO EQUITY RATIO AVG 10Y

0.05

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-640.35%

CURRENT VS 3Y AVG

-36840.80%

CURRENT VS 5Y AVG

-21731.55%

CURRENT VS 10Y AVG

-25783.66%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.13

median of 528 covered companies

CURRENT VS SECTOR MEDIAN

-9389.04%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Dare Bioscience, Inc. (DARE)	$12.43M	-12.08	-1.63	-0.03	-0.06
IRIDEX Corporation (IRIX)vs ›	$12.41M	1.10	0.92	1.14	0.73
Lantern Pharma Inc. (LTRN)vs ›	$11.87M	N/A	6.01	3.01	2.01
Cellectar Biosciences, Inc. (CLRB)vs ›	$12.94M	0.05	0.04	0.04	0.03
Cytosorbents Corporation (CTSO)vs ›	$11.75M	N/A	3.67	2.17	1.48
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.50M	0.01	0.00	0.00	0.00
Vyome Holdings, Inc. (HIND)vs ›	$13.41M	0.00	0.01	0.03	0.20
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.50M	0.00	0.00	0.01	0.02
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.38M	0.00	0.00	0.00	0.01
Biofrontera Inc. (BFRI)vs ›	$11.09M	1.26	0.85	0.72	0.48

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Dare Bioscience, Inc. (DARE)

$12.43M

-12.08

-1.63

-0.03

-0.06

IRIDEX Corporation (IRIX)vs ›

$12.41M

1.10

0.92

1.14

0.73

Lantern Pharma Inc. (LTRN)vs ›

$11.87M

N/A

6.01

3.01

2.01

Cellectar Biosciences, Inc. (CLRB)vs ›

$12.94M

0.05

0.04

0.03

Cytosorbents Corporation (CTSO)vs ›

$11.75M

N/A

3.67

2.17

1.48

Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›

$11.50M

0.01

0.00

Vyome Holdings, Inc. (HIND)vs ›

$13.41M

0.00

0.01

0.03

0.20

Adial Pharmaceuticals, Inc. (ADIL)vs ›

$11.50M

0.00

0.01

0.02

Lisata Therapeutics, Inc. (LSTA)vs ›

$11.38M

0.00

0.01

Biofrontera Inc. (BFRI)vs ›

$11.09M

1.26

0.85

0.72

0.48

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Dare Bioscience, Inc. (DARE)?

The debt to equity ratio for DARE stock is -12.08.

Is Dare Bioscience, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of -12.08 is 21732% below its 5-year average of -0.06, near the low end of its 5-year range (-12.08–2.20).

What is the TTM average debt to equity ratio for Dare Bioscience, Inc. (DARE)?

The TTM average debt to equity ratio for DARE stock is -1.63.

What is the 3Y average debt to equity ratio for Dare Bioscience, Inc. (DARE)?

The 3Y average debt to equity ratio for DARE stock is -0.03.

What is the 5Y average debt to equity ratio for Dare Bioscience, Inc. (DARE)?

The 5Y average debt to equity ratio for DARE stock is -0.06.

What is the 10Y average debt to equity ratio for Dare Bioscience, Inc. (DARE)?

The 10Y average debt to equity ratio for DARE stock is 0.05.

DATE	DEBT TO EQUITY RATIO
2026-06-30	-12.08
2026-03-31	2.20
2025-12-31	0.93
2025-09-30	1.03
2025-06-30	-0.24
2025-03-31	-0.87
2024-12-31	-0.22
2024-09-30	-0.95
2024-06-30	0.57
2024-03-31	-0.15
2023-12-31	-0.28
2023-09-30	-0.09
2023-06-30	-0.11
2023-03-31	0.08
2022-12-31	0.04
2022-09-30	0.02
2022-06-30	0.03
2022-03-31	0.04
2021-12-31	0.01
2021-09-30	0.01
2021-06-30	0.06
2021-03-31	0.18
2020-12-31	-0.66
2020-09-30	-0.62
2020-06-30	3.08
2020-03-31	0.21
2019-12-31	1.82
2019-09-30	0.15
2019-06-30	0.02
2019-03-31	0.04
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.00
2017-09-30	0.00
2017-06-30	0.21
2017-03-31	0.10
2016-12-31	0.98
2016-09-30	0.89
2016-06-30	0.64
2016-03-31	0.51
2015-12-31	0.42
2015-09-30	0.25
2015-06-30	0.21
2015-03-31	0.36
2014-12-31	0.07
2014-09-30	0.07
2014-06-30	0.08
2014-03-31	-0.24
2013-12-31	-2.24
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

-12.08

2026-03-31

2.20

2025-12-31

0.93

2025-09-30

1.03

2025-06-30

-0.24

2025-03-31

-0.87

2024-12-31

-0.22

2024-09-30

-0.95

2024-06-30

0.57

2024-03-31

-0.15

2023-12-31

-0.28

2023-09-30

-0.09

2023-06-30

-0.11

2023-03-31

0.08

2022-12-31

0.04

2022-09-30

0.02

2022-06-30

0.03

2022-03-31

0.04

2021-12-31

0.01

2021-09-30

0.01

2021-06-30

0.06

2021-03-31

0.18

2020-12-31

-0.66

2020-09-30

-0.62

2020-06-30

3.08

2020-03-31

0.21

2019-12-31

1.82

2019-09-30

0.15

2019-06-30

0.02

2019-03-31

0.04

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.00

2017-09-30

0.00

2017-06-30

0.21

2017-03-31

0.10

2016-12-31

0.98

2016-09-30

0.89

2016-06-30

0.64

2016-03-31

0.51

2015-12-31

0.42

2015-09-30

0.25

2015-06-30

0.21

2015-03-31

0.36

2014-12-31

0.07

2014-09-30

0.07

2014-06-30

0.08

2014-03-31

-0.24

2013-12-31

-2.24

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

Debt to Equity Ratio: -12.08

DARE Debt to Equity Ratio

DARE Average Debt to Equity Ratio Chart

DARE Current vs Average Debt to Equity Ratio Chart

DARE Debt to Equity Ratio Metrics

DARE Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

DARE Debt to Equity Ratio History

Related Metrics